Shu Yun Chen
Fortune : - $ au 31/05/2026
Fortune : - $ au 31/05/2026
Shu Yun Chen is currently an Independent Non-Executive Director at Jinxin Eldercare Industry Group Ltd. since 2026, a Director at Jinxin Hospital Management Group Ltd. since 2018, Lead Independent Non-Executive Director at Innovent Biologics, Inc. since 2025, Non-Executive Director at Jinxin Fertility Group Ltd. since 2025, Independent Director at Shanghai Yaohua Pilkington Glass Group Co., Ltd. since 2024, Partner at Capital International, Inc. (Singapore) since 2006, and Partner & Head-China at Capital Group Private Markets, Inc. Former roles include Non-Executive Director at Innovent Biologics, Inc. from 2018 to 2022 and Vice President at J.P.
Morgan Holdings (Hong Kong) Ltd. Education includes an undergraduate degree from Franklin & Marshall College conferred in 1997.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 05/12/2025 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| INNOVENT BIOLOGICS, INC. | Directeur/Membre du Conseil | 03/05/2024 |
| SHANGHAI YAOHUA PILKINGTON GLASS GROUP CO., LTD. | Directeur/Membre du Conseil | 27/06/2024 |
| JINXIN FERTILITY GROUP LIMITED | Directeur/Membre du Conseil | 25/09/2025 |
Capital International, Inc. (Singapore)
Capital International, Inc. (Singapore) Investment ManagersFinance CII-SG is a long-term, specialist manager which focuses on Asian markets while working in close relationship with other Capital entities worldwide. They offer equity, fixed-income and balanced funds invested globally across all asset classes. Research is shared among the Capital Group Companies and is globally integrated. The firm's investment approach is strongly research-oriented. Each potential investment opportunity is subjected to detailed analysis and portfolios are constructed stock by stock in a purely bottom-up approach. The firm's investment strategy is based on a multiple portfolio manager approach where mutual funds are aggregates of separately-managed segments, resulting in diversified portfolios. As a private equity investor, CII-SG looks for opportunities in companies undergoing expansion or restructuring. Criteria include strong management, revenue generation and market position. One of the firm's focuses for private equity investments is the life science field. | Private Equity Investor | 01/01/2006 |
Capital Group Private Markets, Inc.
Capital Group Private Markets, Inc. Investment ManagersFinance Capital Group invests in companies located across the globe. The firm focuses on a broad range of sectors and industries. It participates in early and later stage capital requirements. | Corporate Officer/Principal | - |
Jinxin Hospital Management Group Ltd.
Jinxin Hospital Management Group Ltd. Hospital/Nursing ManagementHealth Services Operates as a hospital | Directeur/Membre du Conseil | 01/06/2018 |
| Sociétés | Poste | Fin |
|---|---|---|
| INNOVENT BIOLOGICS, INC. | Directeur/Membre du Conseil | 25/02/2022 |
J.P. Morgan Holdings (Hong Kong) Ltd.
J.P. Morgan Holdings (Hong Kong) Ltd. Regional BanksFinance Provides banking services | Corporate Officer/Principal | 01/01/2005 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 8 |
|---|---|
Shanghai Yaohua Pilkington Glass Group Co., Ltd.
Shanghai Yaohua Pilkington Glass Group Co., Ltd. Industrial SpecialtiesProcess Industries Manufactures and distributes processed glass products | Process Industries |
Capital International, Inc. (Singapore)
Capital International, Inc. (Singapore) Investment ManagersFinance CII-SG is a long-term, specialist manager which focuses on Asian markets while working in close relationship with other Capital entities worldwide. They offer equity, fixed-income and balanced funds invested globally across all asset classes. Research is shared among the Capital Group Companies and is globally integrated. The firm's investment approach is strongly research-oriented. Each potential investment opportunity is subjected to detailed analysis and portfolios are constructed stock by stock in a purely bottom-up approach. The firm's investment strategy is based on a multiple portfolio manager approach where mutual funds are aggregates of separately-managed segments, resulting in diversified portfolios. As a private equity investor, CII-SG looks for opportunities in companies undergoing expansion or restructuring. Criteria include strong management, revenue generation and market position. One of the firm's focuses for private equity investments is the life science field. | Finance |
Franklin & Marshall College
Franklin & Marshall College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Innovent Biologics, Inc.
Innovent Biologics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures biopharmaceutical products | Health Technology |
J.P. Morgan Holdings (Hong Kong) Ltd.
J.P. Morgan Holdings (Hong Kong) Ltd. Regional BanksFinance Provides banking services | Finance |
Capital Group Private Markets, Inc.
Capital Group Private Markets, Inc. Investment ManagersFinance Capital Group invests in companies located across the globe. The firm focuses on a broad range of sectors and industries. It participates in early and later stage capital requirements. | Finance |
Jinxin Fertility Group Ltd.
Jinxin Fertility Group Ltd. Medical/Nursing ServicesHealth Services Provides assisted reproductive medical and fertilization treatment services | Health Services |
Jinxin Hospital Management Group Ltd.
Jinxin Hospital Management Group Ltd. Hospital/Nursing ManagementHealth Services Operates as a hospital | Health Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national